SCHEMBL29377339

SCHEMBL29377339

Cc1cc2ncc(Br)cc2n1C(=O)OC(C)(C)C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRG2 P18507 2/20 0.38
GABRB3 P28472 2/20 0.38
GABRA5 P31644 2/20 0.38
AAK1 Q2M2I8 1/20 0.36
GABRA1 P14867 1/20 0.36
GABRA2 P47869 1/20 0.36
GABRA6 Q16445 1/20 0.36
HSD17B10 Q99714 2/20 0.34
KDM4E B2RXH2 2/20 0.34
ALDH1A1 P00352 1/20 0.34
NR1H2 P55055 3/20 0.33
CCNB2 O95067 1/20 0.33
CDK1 P06493 1/20 0.33
CCNB1 P14635 1/20 0.33
GSK3B P49841 1/20 0.33
CCNB3 Q8WWL7 1/20 0.33
PIK3R1 P27986 1/20 0.31
PIK3CA P42336 1/20 0.31
AURKA O14965 1/20 0.31
CDK2 P24941 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16729363 1.00 GABRG2 (0.38) GABRG2GABRB3GABRA5AAK1GABRA1
SCHEMBL29375035 0.82 GABRG2 (0.37) GABRG2GABRB3GABRA5GABRA1GABRA2
SCHEMBL16729358 0.82 GABRG2 (0.37) GABRG2GABRB3GABRA5GABRA1GABRA2
SCHEMBL16729359 0.82 GABRG2 (0.37) GABRG2GABRB3GABRA5GABRA1GABRA2
SCHEMBL29374655 0.82 GABRG2 (0.37) GABRG2GABRB3GABRA5GABRA1GABRA2
SCHEMBL25909836 0.80 NR1H2 (0.39) GABRG2GABRB3GABRA5KDM4EALDH1A1
SCHEMBL16720664 0.80 HSD17B10 (0.39) HSD17B10KDM4EALDH1A1
SCHEMBL22091266 0.79 HPGDS (0.35) GABRG2GABRB3GABRA5KDM4EUSP30
SCHEMBL30466269 0.78 USP30 (0.36) GABRG2GABRB3GABRA5AAK1GABRA1
SCHEMBL25909825 0.78 USP30 (0.36) GABRG2GABRB3GABRA5AAK1GABRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11958873-B2 Proteasome activity enhancing compounds Kineta, Inc. (US) 2024-04-16 US disclosed
US-20230242557-A9 PROTEASOME ACTIVITY ENHANCING COMPOUNDS Kineta, Inc. 2023-08-03 US disclosed
US-20220298181-A1 PROTEASOME ACTIVITY ENHANCING COMPOUNDS PROTEOSTASIS THERAPEUTICS INC (US) 2022-09-22 US disclosed
US-11242361-B2 Proteasome activity enhancing compounds PROTEOSTASIS THERAPEUTICS, INC. (US) 2022-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242557-A9 PROTEASOME ACTIVITY ENHANCING COMPOUNDS PSMG3, PSMB1, PSMC1 GABRG2 3723/4885GABRB3 3453/4885GABRA5 3849/4885
US-20220298181-A1 PROTEASOME ACTIVITY ENHANCING COMPOUNDS PSMG3, PSMB1, PSMC1 GABRG2 3723/4885GABRB3 3453/4885GABRA5 3849/4885
US-11242361-B2 Proteasome activity enhancing compounds PSMG3, PSMB1, PSMC1 GABRG2 3723/4885GABRB3 3453/4885GABRA5 3849/4885
US-11958873-B2 Proteasome activity enhancing compounds PSMG3, PSMB1, PSMC1 GABRG2 3723/4885GABRB3 3453/4885GABRA5 3849/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.